| 发明名称 |
FACTOR VIII VARIANTS HAVING A DECREASED CELLULAR UPTAKE |
| 摘要 |
The present invention relates to modified coagulation factors. In particular, the present invention relates to modied Factor VIII molecules having decreased cellular uptake. |
| 申请公布号 |
US2017066813(A1) |
申请公布日期 |
2017.03.09 |
| 申请号 |
US201615355475 |
申请日期 |
2016.11.18 |
| 申请人 |
Novo Nordisk A/S ;Sanquin Blood Supply Foundation |
发明人 |
Meems Henriet;Meijer Alexander Benjamin;Mertens Koenraad;Olsen Ole Hvilsted;Lamberth Kasper;Noerby Peder Lisby;Johnsen Laust Bruun;Kjalke Marianne Hjortnes;Stennicke Henning Ralf;Voorberg Johannes Jacobus;Van Den Biggelaar Maartje |
| 分类号 |
C07K14/755 |
主分类号 |
C07K14/755 |
| 代理机构 |
|
代理人 |
|
| 主权项 |
1. A recombinant FVIII variant having FVIII activity, wherein said variant comprises 2-10 substitutions of surface accessible positively charged amino acid residues in the FVIII C1 foot and/or the C2 foot, wherein said surface accessible charged amino acid residues are substituted with alanine or glutamine and wherein the substitutions result in decreased cellular uptake of said FVIII variant. |
| 地址 |
Bagsvaerd DK |
